Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of fispemifene in the treatment of hypogonadal men with erectile dysfunction unresponsive to PDE5 [phosphodiesterase-5] inhibitors: an 8-week, randomized, double-blind, placebo-controlled study

Trial Profile

Efficacy and safety of fispemifene in the treatment of hypogonadal men with erectile dysfunction unresponsive to PDE5 [phosphodiesterase-5] inhibitors: an 8-week, randomized, double-blind, placebo-controlled study

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2010

At a glance

  • Drugs Fispemifene (Primary)
  • Indications Erectile dysfunction; Hypogonadism
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top